ReviewFrontiers in microbiology2023
Review in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 34 citations in OpenAlex.
- Genomic characterization of KPC-2 and NDM coproducing carbapenem-resistantMicrobiology spectrum · 2026Article
- OmpK35/36 modulate the virulence of hypervirulent Klebsiella pneumoniae by regulating capsular polysaccharide export.BMC microbiology · 2026Article
- Advances in CRISPR-Cas for Diagnosis and Treatment ofPathogens (Basel, Switzerland) · 2026Review
- Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections.Antimicrobial agents and chemotherapy · 2026Article
- Shifting of blaBMC genomics · 2026Article
- Genomic characterisation and antimicrobial resistance ofFrontiers in cellular and infection microbiology · 2026Article
- Antibiotics for Intra-Abdominal Infections: When, Which, How and How Long?Antibiotics (Basel, Switzerland) · 2025Review
- Rapid replacement of blaKPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection.The Journal of antimicrobial chemotherapy · 2025Article
- The mechanisms of antibiotic resistance and drug resistance transmission of Klebsiella pneumoniae.The Journal of antibiotics · 2025Review
- Prevalence of polymyxin heteroresistance in Klebsiella pneumoniae under sustained antibiotic selection during experimental evolution.Archives of microbiology · 2025Article
- Mechanism of virulence polymorphism in CR-hvKP strains from the same source.Microbiology spectrum · 2025Article
- Mobile genetic elements inJournal of bacteriology · 2025Review
- Dissemination ofMicrobiology spectrum · 2025Article
- Adaptive evolution of extensive drug resistance and persistence in epidemic ST11 KPC-producingAntimicrobial agents and chemotherapy · 2025Article
- Unseen Enemy: Mechanisms of Multidrug Antimicrobial Resistance in Gram-Negative ESKAPE Pathogens.Antibiotics (Basel, Switzerland) · 2025Review
- Recent Advances in Understanding the Clinical Implications of Heterogeneous Drug Resistance inInfection and drug resistance · 2025Review
- Disruption of zinc homeostasis reverses tigecycline resistance inFrontiers in cellular and infection microbiology · 2025Article
- Molecular and virulence differences ofFrontiers in microbiology · 2025Article
- Ecological and evolutionary mechanisms driving within-patient emergence of antimicrobial resistance.Nature reviews. Microbiology · 2024Review
- Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use.World journal of emergency surgery : WJES · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.